New study checks if Long-Acting HIV shots work for all subtypes

NCT ID NCT07370649

Recruiting now Disease control Sponsor: Pomeranian Medical University Szczecin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a long-acting injectable HIV treatment works in people with HIV-1 subtype A6, a common type in Eastern Europe. Researchers will compare medical records from 250 adults in Poland, Germany, and the Czech Republic who have already received the shots. The goal is to see if knowing your HIV subtype helps doctors choose the best treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1 SUBTYPE A6 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1 SUBTYPE A6 INFECTION HIV-1 SUBTYPE B INFECTION HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 INFECTION VIROLOGICALLY SUPPRESSED HIV-1 INFECTION RECEIVING LONG-ACTING ANTIRETROVIRAL THERAPY

Contacts and locations

Locations

Hospital Na Bulovce Praque HIV Centre, Department of Infectious Diseases
RECRUITING

Prague, Czechia
Katedra Chorób Zakaźnych i Niedoborów Immunologicznych
NOT_YET_RECRUITING

Szczecin, West Pomeranian Voivodeship, 71-455, Poland
MainFachArzt
RECRUITING

Frankfurt, Germany
Szpitale Pomorskie
RECRUITING

Gdansk, Poland
Wojewódzki Szpital Obserwacyjno-Zakaźny
RECRUITING

Bydgoszcz, Poland
Wojewódzki Szpital Zakaźny w Warszawie
RECRUITING

Warsaw, Poland
Wrocławskie Centrum Zdrowia
RECRUITING

Wroclaw, Poland